Analysts Set Sana Biotechnology, Inc. (NASDAQ:SANA) PT at $9.50

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $9.50.

Several research firms have commented on SANA. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 target price on the stock. Wedbush raised their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Wall Street Zen raised shares of Sana Biotechnology from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings cut shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Finally, Morgan Stanley reissued an “overweight” rating and set a $12.00 target price on shares of Sana Biotechnology in a research note on Friday, March 13th.

Hedge Funds Weigh In On Sana Biotechnology

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its position in shares of Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after purchasing an additional 1,375,029 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after purchasing an additional 1,371,775 shares in the last quarter. Integral Health Asset Management LLC boosted its position in shares of Sana Biotechnology by 33.3% during the 3rd quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $7,100,000 after purchasing an additional 500,000 shares in the last quarter. Rafferty Asset Management LLC bought a new position in shares of Sana Biotechnology during the 3rd quarter valued at about $951,000. Finally, Corient Private Wealth LLC boosted its position in shares of Sana Biotechnology by 264.7% during the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock valued at $3,101,000 after purchasing an additional 824,505 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

SANA stock opened at $3.07 on Wednesday. Sana Biotechnology has a fifty-two week low of $1.63 and a fifty-two week high of $6.55. The firm’s 50-day simple moving average is $3.26 and its 200 day simple moving average is $3.95. The stock has a market cap of $854.36 million, a PE ratio of -3.30 and a beta of 2.17.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Equities analysts forecast that Sana Biotechnology will post -0.61 EPS for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.